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Abstract 
Background: Understanding of the effects of HIV and anti-retroviral treatment (ART) on 
Mycobacterium tuberculosis (M.tb) transmission dynamics remains limited.  We 
undertook a cross-sectional study of household contacts of smear-positive pulmonary 
tuberculosis cases to assess the effect of established ART on the infectiousness of TB 
Method: Prevalence of tuberculin skin test (TST) positivity was compared between 
contacts aged 2-10 years of index cases who were: HIV-negative; HIV-positive not on 
ART; on ART <1 year and on ART for ≥1 year. Random effects logistic regression was 
used to take account of clustering within households.   
Results: M.tb infection prevalence in contacts of HIV-negative, HIV-positive on ART ≥1 
year and HIV-positive not on ART/ on ART <1 year index cases was 44%, 21% and 22% 
respectively. Compared to contacts of HIV-positive index cases not on ART or recently 
started on ART, the odds of TST positivity was similar in contacts of HIV-positive index 
cases on ART ≥1 year (aOR 1.0; 95% CI 0.3 – 3.7).  The odds were 2.9 times higher in 
child contacts of HIV-negative index cases (aOR 2.9; 95% CI 1.0 – 8.2).  
Conclusions: We found no evidence that established ART increased the infectiousness 
of smear positive HIV-positive index cases. 
Word count: 196 
 
Key Words: M.tb infection; infectiousness; tuberculosis; antiretroviral treatment; 
HIV  
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INTRODUCTION 1 
The human immunodeficiency virus (HIV) pandemic continues to challenge global 2 
tuberculosis (TB) control,1,2 yet our understanding of the effects of HIV and anti-3 
retroviral treatment (ART) on Mycobacterium tuberculosis (M.tb) transmission 4 
dynamics remains limited.3-7  5 
 6 
In HIV-positive individuals, ART reduces TB incidence across all CD4 cell counts,8 yet 7 
despite long-term ART, TB incidence remains higher than in HIV-negative people in 8 
both high and low TB-burden settings.9,10 As life expectancy is greatly extended by ART, 9 
the cumulative lifetime risk of TB for HIV-positive people remains very high.9 While HIV-10 
positive TB patients with advanced immunosuppression are less likely to transmit to 11 
household contacts than their HIV-negative counterparts,11-17 partly mediated through 12 
a lower bacillary load in sputum,11,16,17 ART may increase the infectiousness of TB by 13 
shifting the clinical manifestation to be more similar to HIV-negative patients.18,19 14 
 15 
Concerns have been raised that the increased life-expectancy and possible increased 16 
infectiousness due to ART might increase TB incidence at a population-level.20 This 17 
might be negated by reduced HIV transmission,21,22   but a rebound in TB incidence, 18 
exceeding levels present before ART roll-out, is possible if good adherence to ART is 19 
not sustained.23 Programmatic data from South Africa, Malawi and Zimbabwe have 20 
shown a reduction in TB incidence, as inferred from trends in TB case notification, in 21 
association with ART scale-up.24,25  However, short-term reductions in TB incidence 22 
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may be due to protection from progression to disease rather than a reduction in M.tb 23 
transmission.  24 
 25 
We examine the effect of ART on M.tb transmission by measuring the prevalence of 26 
M.tb infection among child contacts of adult smear-positive tuberculosis cases.     27 
 28 
 29 
METHODS 30 
 31 
Study setting 32 
Karonga District, northern Malawi, is predominantly rural, with an adult HIV prevalence 33 
of 9% and new smear-positive TB incidence of 87 per 100,000 adults per year.26 60% of 34 
TB cases are HIV-positive.26 The first ART clinic opened in 2005 and by 2012, 16 clinics 35 
in the district were certified to initiate and provide ART.27  36 
 37 
Study design 38 
A cross-sectional household study of all diagnosed smear-positive TB cases in the 39 
district was conducted from January 2013 to April 2015. Households were eligible if a 40 
smear-positive case had lived there for at least 2 weeks after the onset of symptoms 41 
and prior to initiation of treatment.  Bacteriological, demographic and clinical (including 42 
HIV and ART status) data from all patients starting TB treatment in the district have 43 
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been collected in a TB case cohort study since 1988 to date, which has been previously 44 
described.26,28 45 
 46 
Households were visited approximately 6 weeks after TB diagnosis of index case (date 47 
of first smear-positive sputum).  All children aged 2 to 10 years-old resident within the 48 
household were included. A tuberculin skin test (TST) was administered and read 49 
according to standard international guidelines29 using 2 international units of RT23 50 
(Statens Serum Institute, Copenhagen, Denmark) and induration was measured 48-72 51 
hours later.  A positive TST was defined as induration ≥ 10mm.  Children under the age 52 
of 2 years were excluded to minimize misclassification of infection status due to false-53 
positive TST as a result of recent BCG vaccination.30   54 
 55 
A questionnaire was completed which included data on demographics, BCG vaccination 56 
status, exposure to index case (whether index case was mother, duration of sleeping in 57 
same room and of living in the same household whilst index case was symptomatic), 58 
and household characteristics (number of residents, socio-economic indicators 59 
including quality of dwelling place).  A composite score for household socioeconomic 60 
status was created using head of household employment, number of assets, food 61 
security and availability of soap, and a composite score for quality of dwelling place 62 
was based on building materials, type of roof, number of rooms, water source, 63 
presence of glass windows, electricity and latrine type. 64 
 65 
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Any child with symptoms suggestive of TB (fever, weight loss, failure to thrive, night 66 
sweats or cough) was reviewed by a clinician and referred to the district hospital where 67 
appropriate.  All children aged <5 years without evidence of active disease were 68 
commenced on 6-month isoniazid preventive treatment (5mg/kg once daily) 69 
irrespective of TST induration size (as per Malawi National TB programme guidelines).31   70 
 71 
Ethics approval 72 
The study was approved by the Malawi National Health Sciences Research Committee 73 
(#1049) and the London School of Hygiene & Tropical Medicine Ethics committee 74 
(#6285).  At the time of study recruitment, smear positive pulmonary TB patients were 75 
asked for written consent to visit their household(s) to screen household members for 76 
infection and disease.  Written informed consent was then obtained from a parent or 77 
guardian of each participating child at the time of household visit. 78 
 79 
Statistical analysis 80 
Prevalence of tuberculin skin test (TST) positivity, was compared between household 81 
contacts by HIV and ART status of the index case, distinguishing those not on ART or on 82 
ART for <1 year and on ART for ≥1 year at tuberculosis diagnosis.  We performed 83 
univariable analyses for covariates known to be risk factors for M.tb infection, and they 84 
were assessed as confounders of the association between HIV/ART status and TST 85 
positivity, first individually and then in a multivariable model, using random effects 86 
logistic regression to account for clustering within household.   87 
 88 
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Sputum smear grade and duration of symptoms were not included in the initial 89 
multivariable model as they were considered to be on the causal pathway between 90 
HIV/ART status and prevalence of TST positivity in the child contact.  They were 91 
examined as mediators of the association in the subsequent models.  92 
 93 
Sensitivity analyses:  The analysis was repeated (i) grouping all patients on ART 94 
irrespective of time on ART, (ii) separating patients on ART for ≥2 years, and (iii) using a 95 
TST cut-off ≥ 15mm. 96 
 97 
 98 
RESULTS 99 
388 child contacts of 187 index cases were eligible for inclusion (Figure 1).  309 child 100 
contacts had a TST placed and read within 48-72 hours (80%; 153 index cases). HIV/ART 101 
status was missing for 3 index cases (7 contacts).  Therefore 302 child contacts of 150 102 
index cases were included in the final analysis.  One hundred and seventy-seven 103 
children (58.4%) had no induration; the frequency distribution of those children with 104 
non-zero TST induration (n=125) is shown in Figure 2. 105 
 106 
Index case characteristics  107 
Of the 150 index cases, 63% were male.  Median age was 33.6 years (interquartile 108 
range [IQR] 28.2 – 39.3) for female index cases and 37.6 years (IQR 30.6 – 44.9) for 109 
male.  22% of index cases were on ART at TB diagnosis, with a median duration on ART 110 
of 2.8 years (IQR 1.2 – 4.5; n=33). Table 1 shows index case characteristics by HIV/ART 111 
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status. The median duration of symptoms prior to TB diagnosis (by self-report) was 112 
shortest in HIV-positive on ART ≥1 year (8.3 weeks IQR: 7.0 – 16.3).   113 
 114 
TST positivity in child contacts  115 
The prevalence of TST positivity among all child contacts was 34.4%.  TST positivity in 116 
the child contacts of HIV-positive index cases not on ART was 23.1% (15/65); as there 117 
were only 11 child contacts of 8 HIV-positive index cases on ART for <1 year (TST 118 
positivity 18.2%) this category was combined with the HIV-positive not on ART index 119 
cases. TST positivity was 44.1% (75/170), 21.4% (12/56) and 22.4 % (17/76) in contacts 120 
of index cases who were HIV-negative, HIV-positive on ART ≥1 year, and HIV-positive 121 
not on ART/on ART for <1 year, respectively (Table 2).  122 
 123 
Factors associated with TST positivity in child contacts included: HIV/ART status of 124 
index case; sex of index case; whether index case was the mother; index case sputum 125 
smear grade; and degree of exposure of contact (Table 2). 126 
 127 
Compared to contacts of HIV-positive index cases not on ART or on ART for <1 year, the 128 
odds of a positive TST were higher in the contacts of HIV-negative index cases (crude 129 
OR 4.3: 95% CI 1.4-13.1, reducing to OR 2.9: 95%CI 1.0–8.2 after adjustment for socio-130 
demographic factors) but not in contacts of HIV-positive index cases who had been on 131 
ART for ≥ 1 year (crude OR 1.1: 95%CI 0.3–4.6, adjusted OR 1.0; 95% CI 0.3–3.7, Table 132 
2).  Further adjustment assessed the effect of factors that may be on the causal 133 
pathway. Adjustment for duration of symptoms (model2a, Table 3) made little 134 
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difference to the odds of TST positivity in contacts of HIV-negative index cases but 135 
adjustment for smear grade (model 2b) reduced the association (aOR 2.2: 95% CI 0.8–136 
6.3). Among contacts of HIV-positive index cases there was no association of TST 137 
positivity with ART duration in any model (Table 3).   138 
 139 
The results of the sensitivity analyses are also shown in Table 3.  Using a cut-off TST 140 
≥15mm, regrouping those on ART ignoring duration, or separating those on ART >2 141 
years made little difference to the results 142 
 143 
 144 
DISCUSSION 145 
 146 
We found no evidence that child contacts of HIV-positive TB patients on ART were 147 
more likely to have a positive TST compared to child contacts of HIV-positive TB 148 
patients not on ART.  However, child contacts of HIV-negative individuals had nearly 149 
three times the odds of having a positive TST compared to child contacts of HIV-150 
positive TB patients not on ART; this was partly explained by differences in the degree 151 
of smear positivity.  152 
 153 
Some TB household contact studies have found no difference in infectiousness 154 
between HIV-positive TB patients compared to HIV-negative TB patients if HIV-positive 155 
index cases were less immunosuppressed (CD4>250)16 or were smear-positive and/or 156 
had cavitatory disease.17  Heterogeneity observed in the estimates of infectiousness of 157 
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HIV-positive TB patients compared to HIV-negative TB patients has been well-158 
described, although no studies to date have examined the effect of ART status of the 159 
HIV-positive index case. Possible reasons for heterogeneity seen include differences in 160 
patient eligibility (smear-positive only vs all TB patients), study settings (high vs low HIV 161 
and TB background prevalence), household contacts screened for M.tb infection 162 
(adults and children vs children only) and study-related biases, such as exposure 163 
assessment bias and recall bias.16,17,32,33 Study calendar period may also influence the 164 
estimates of infectiousness as the degree of immunosuppression of HIV-positive TB 165 
cases on a population-level will be a function of the maturity of the HIV epidemic and 166 
the time since roll-out of ART. 167 
 168 
The lack of evidence for increased infectiousness in TB patients established on ART, 169 
compared to those not on ART in our study may be due to earlier diagnosis resulting in 170 
a shorter duration of infectiousness.  However, adjusting for duration of symptoms in 171 
model 2a did not alter the odds of a positive TST in contacts of index cases who had 172 
been on ART ≥ 1 years. This might be due to the fact that duration of symptoms at time 173 
of TB diagnosis is notoriously difficult to recall accurately. Interestingly, a 174 
contemporaneous study of attendance at the HIV/ART clinic undertaken at the Karonga 175 
District Hospital found that HIV-positive individuals on ART attended clinic much more 176 
regularly than those not on ART; median number of visits per year were 5 (IQR 4 – 6) 177 
for ART patients and 1 (IQR 1-2) for HIV patients not on ART (unpublished data).  This 178 
gives much greater opportunity for early diagnosis of TB. Another reason for the 179 
absence of evidence for increased infectiousness in TB patients established on ART may 180 
 12 
 
be that in our population in northern Malawi, the effect of ART is masked by the 181 
degree of immunodeficiency of the index case because ART is started in individuals 182 
with more advanced HIV infection.   183 
CD4 cell count testing is not done routinely in Karonga, northern Malawi resulting in 184 
the absence of a biological marker for the level of immunosuppression of HIV-positive 185 
TB patients and degree of immune reconstitution in those established on ART in this 186 
study. Limitations of our study also include the absence of radiological data to assess 187 
extent of lung cavitation by HIV/ART status. These data would have helped to interpret 188 
the apparent lack of effect of ART on infectiousness. Knowing the HIV status of the 189 
child contacts would have also strengthened this study, as an HIV-positive child with 190 
advanced immunosuppression may be more likely to have a false-negative TST than an 191 
HIV-negative child, and an HIV-positive child is more likely to be resident in the 192 
household of an HIV-positive index case.  This is one potential explanation for the lower 193 
prevalence of M.tb infection in the child contacts of index cases with HIV infection 194 
irrespective of ART status found in this study. However, ART for prevention of mother 195 
to child transmission is widely used and the proportion of infected children will be very 196 
low.  197 
 198 
Conclusion 199 
We found a higher prevalence of M.tb infection among child contacts of HIV-negative 200 
tuberculosis patients compared to contacts of HIV-positive index cases, irrespective of 201 
ART status.  We found no evidence that HIV-positive index cases on ART for ≥ 1 year at 202 
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tuberculosis diagnosis were more likely to transmit than other HIV-positive index cases. 203 
Frequent health service contacts of HIV-positive individuals on ART leading to prompt 204 
diagnosis of TB may mitigate the effects of any increase in infectiousness.  Further 205 
studies are required to definitively establish whether ART has a biological effect on the 206 
infectiousness of HIV-positive TB patients.207 
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TABLES AND FIGURES 
Table 1. Index case characteristics by HIV/ART status of index case (n=150) 
sd standard deviation; IQR interquartile range 
 
 
 
Table 2. Demographic and clinical characteristics of index case and contact: risk factors 
for TST positivity (n=302) 
 
  HIV/ART status of index case 
Case characteristics 
HIV- HIV+ ART ≥1 yr HIV+ ART < 1yr HIV+ no ART 
(N=82) (N=25) (N=8) (N=35) 
Male (%) 50 (61.7) 14 (56.0) 5 (62.5) 25 (71.4) 
Age in year (mean (sd)) 36.1 (14.7) 39.9 (6.1) 36.1 (4.8) 36.7 (8.7) 
Index case mother (%) 15 (18.3) 7 (28.0) 2 (25.0) 5 (14.3) 
Smear grade Scanty 2 (2.5) 3 (12.0) 1 (12.5) 4 (11.4) 
 +1 11 (13.4) 4 (16.0) 2 (25.0) 9 (25.7) 
 +2 27 (32.9) 9 (36.0) 3 (37.5) 4 (11.4) 
 +3 42 (51.2) 9 (36.0) 2 (25.0) 18 (51.5) 
Duration of symptoms in weeks 
  (median (IQR)) 
13.2 (7.6 – 20.6) 8.3 (7.0 – 16.3) 18.6 (8.2 – 28.6) 12.4 (8.0 – 19.7) 
Characteristics 
TST≥10mm 
Crude OR (95% CI) P value (N=302) 
n/N (%) 
Index Case HIV/ART status HIV+ no ART/ ART<1y 17/76 (22.4) 1 0.009 
  HIV+ on ART ≥ 1y 12/56 (21.4) 1.1 (0.3 – 4.6)  
  HIV- 75/170 (44.1) 4.3 (1.4 – 13.1)  
 Sex Female 52/116 (44.8) 1 0.01 
  Male 52/186 (28.0) 0.3 (0.1 – 0.8)  
 Age (years) <30 35/86 (41.9) 1 0.3 
  30 - 44 53/156 (34.0) 0.6 (0.2 – 1.7)  
  ≥45 15/60 (25.0) 0.3 (0.1 – 1.3)  
 Index case relationship Not mother 70/243 (28.8) 1 0.002 
  Mother 34/59 (57.6) 4.7 (1.7 – 13.0)  
 Smoker No 72/207 (34.8) 1 0.8 
  Yes 32/95 (33.7) 0.9 (0.3 – 2.5)  
 Sputum smear grade Scanty 1/19 (5.3) 0.02 (0.001 – 0.5) 0.005 
  +1 12/57 (21.1) 0.2 (0.06 – 0.8)  
  +2 35/92 (38.0) 0.7 ( 0.2 – 1.9)  
  +3 56/134 (41.8) 1  
 < 8 34/118 (28.8) 1 0.1 
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OR odds ratio; CI confidence interval; *missing BCG scar status on 13 child contacts
 
Duration of symptoms 
(weeks) 
≥ 8 70/184 (38.0) 2.1 (0.8 – 5.6)  
Contact Sex Female 52/148 (35.1) 1 0.6 
  Male 52/154 (33.8) 0.8 (0.4 – 1.7)  
 BCG scar* No  17/41 (41.5) 1 0.3 
  Yes 82/248 (33.1) 0.6 (0.2 – 1.7)  
 Age (years) 2 - 3 30/75 (40.0) 1 0.7 
  4 - 5 24/62 (38.7) 1.2 (0.4 – 3.3)  
  6 - 7 22/77 (28.6) 0.7 (0.3 – 1.7)  
  ≥ 8 28/88 (31.8) 0.8 (0.3 – 1.9)  
 
Degree of exposure to 
index case whilst 
symptomatic 
Resident 44/175 (25.1) 1 0.008 
 Sleep same room ≤ 30days 16/46 (34.8) 1.5 (0.5 – 4.3)  
 Sleep same room > 30days 42/81 (51.9) 4.0 (1.7 – 10.4)  
Household No. of adults 1 - 2 42/101 (41.6) 1 0.3 
  3 - 4 47/139 (33.8) 0.6 (0.2 – 1.7)   
  ≥ 5 15/62 (24.2) 0.3 (0.1 – 1.3)  
 Socio-economic  Lowest score 54/148 (36.5) 1 0.08 
  Middle 33/80 (41.3) 1.3 (0.4 – 3.9  
  Highest score 17/74 (23.0) 0.3 (0.09 – 1.1)  
 Quality of dwelling 
score 
lowest 28/64 (43.8) 1 0.1 
  middle 45/118 (38.1) 0.6 (0.2 – 2.1)  
  highest 31/117 (26.5) 0.3 (0.08 – 1.0)  
 
Crowding 
(persons/room) 
1 - 2 45/131 (34.4) 1 0.6 
  3 - 4 45/138 (32.6) 1.0 (0.4 – 2.7)  
   ≥ 5 14/33 (42.2) 2.3 (0.5 – 11.7)  
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Table 3. Multivariable analysis of association of HIV/ART status of index case with TST positivity in child contacts 
 a Adjusted for household clustering; age and sex of index case; age and sex of contact; degree of exposure of contact to case; household SES; quality of dwelling structure; whether index case was the 
mother; and number of adults in the household 
b Adjusted for household clustering and for all risk factors in the model 1 plus duration of symptoms 
c Adjusted for household clustering and for all risk factors in the model 1 plus duration of symptoms and smear grade 
 
 
 
 TST positive 
(n=302) 
Crude OR  
Multivariable model 1a 
(n=302) 
 
Multivariable model 2ab 
(n=302) 
 
Multivariable model 2bc 
(n=302) 
 
 
n/N (%) OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Index case 
HIV/ART 
status 
HIV+ no ART/ ART<1y 17/76 (22.4) 1 0.009 1 0.05 1 0.06 1 0.2 
HIV+ on ART≥1y 12/56 (21.4) 1.1 (0.3 – 4.6)  1.0 (0.3 – 3.7) 
 
1.1 (0.3 – 4.4) 
 
0.9 (0.2 – 3.4) 
 
HIV- 75/170 (44.1) 4.3 (1.4 – 13.1)  2.9 (1.0 – 8.2)  3.0 (1.0 – 8.7)  2.2 (0.8 – 6.3)  
 
          
Sensitivity analyses 
          
 HIV+ no ART 15/65 (23.1) 1 0.009 1 0.05 1 0.06 1 0.2 
 HIV+ on ART 14/67 (20.9) 0.9 (0.2 – 3.5)  0.9 (0.3 – 3.3)  1.0 (0.3 – 3.7)  0.9 (0.2 – 3.3)  
 HIV- 75/170 (44.1) 3.8 (1.2 – 12.2)  2.8 (1.0 – 8.1)  2.9 (1.0 – 8.5)  2.2 (0.7 – 6.4)  
 
   
  
 
 
 
   
 HIV+ no ART 15/65 (23.1) 1 0.03 1 0.1 1 0.1 1 0.3 
 HIV+ on ART<2y 8/41 (19.5) 0.9 (0.1 – 5.5)  0.8 (0.1 – 4.2)  0.8 (0.1 – 4.3)  0.6 (0.1 –3.5)  
 HIV+ on ART ≥2y 6/26 (23.1) 0.9 (0.2 – 4.3)  1.0 (0.2 – 4.8)  1.2 (0.3 – 5.9)  1.2 (0.2 – 5.6)  
 HIV- 75/170 (44.1) 3.8 (1.2 – 12.2)  2.8 (1.0 – 8.1)  2.9 (1.0 – 8.5)  2.2 (0.7 – 6.5)  
            
TST≥15mm            
 HIV+ no ART/ ART<1y 12/76 (15.8) 1 0.008 1 0.08 1 0.1 1 0.2 
 HIV+ on ART ≥ 1y 7/56 (12.5) 0.6 (0.1 – 3.5)  0.6 (0.1 – 2.8)  0.7 (0.1 – 3.4)  0.5 (0.1 – 2.4)  
 HIV- 58/170 (34.1) 4.2 (1.2 – 15.0)  2.3 (0.7 – 7.5)  2.4 (0.7 – 8.1)  1.7 (0.5 – 5.5)  
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Figure 1.  Study flowchart: TB case through to child contact TST data included in 
analysis 
  
388 child contacts
187 (78%) index cases with 
household contacts aged 2 to 10 years
Eligible smear-positive TB index cases  
n=318
HIV-                            164 (52%)  
HIV+ on ART                74 (23%)  
HIV+ not on ART          60 (19%) 
HIV unknown                20 (6%)
HIV-                           122 (51%)  
HIV+ on ART               60 (25%)  
HIV+ not on ART         48 (20%) 
HIV unknown                 9 (4%)
244 TB index case household consented 
of 239 (75%) index cases
HIV-                              92 (52%)  
HIV+ on ART                38 (23%)  
HIV+ not on ART          40 (23%) 
HIV unknown                  3 (2%)
HIV/ART status of index case
309 (80%) child contacts had TST placed 
and read within 48-72hrs
HIV-                            207 (53%) 
HIV+ on ART                85 (22%) 
HIV+ not on ART          88 (23%)  
HIV unknown                 8  (2%)
82 HIV-                       170 (55%)  
33 HIV+ on ART          67  (22%)  
35 HIV+ not on ART    65  (21%)  
3 HIV unknown             7   (2%)
170         82 HIV- index cases 
56           25 HIV+ on ART ≥ 1yr 
76           43 HIV+ on ART < 1 yr / no ART
No. of child contacts included in the 
analysis (n=302)
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Figure 2. Histogram illustrating the frequency distribution of non-zero induration in 
child contacts (n=125) 
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